Mortality in acromegaly diagnosed in older individuals in Spain is higher in women compared to the general spanish population

Biagetti, Betina; Iglesias, Pedro; Villar-Taibo, Rocío; Moure Rodríguez, María Dolores; Paja Fano, Miguel; Araújo-Castro, Marta; Ares, Jessica; Álvarez-Escola, Cristina; Vicente, Almudena; Álvarez Guivernau, Èlia; Novoa-Testa, Iria; Guerrero-Pérez, Fernando; Cámara, Rosa; Lecumberri, Beatriz; García Gómez, Carlos; Bernebéu, Ignacio; Manjón, Laura; Gaztambide, Sonia; Cordido, Fernando; Webb, Susan; Menéndez-Torre, Edelmiro Luis; Díez, Juan José; Simó Canonge, Rafael; Puig-Domingo, Manuel

Title

Date

2023-03-14

Citation

Biagetti B, Iglesias P, Villar-Taibo R, Moure MD, Paja M, Araujo-Castro M, Ares J, Álvarez-Escola C, Vicente A, Guivernau ÈÁ, Novoa-Testa I, Perez FG, Cámara R, Lecumberri B, Gómez CG, Bernabéu I, Manjón L, Gaztambide S, Cordido F, Webb SM, Menéndez-Torre EL, Díez JJ, Simó R, Puig-Domingo M. Mortality in acromegaly diagnosed in older individuals in Spain is higher in women compared to the general spanish population. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2193-2202.

Abstract

[Abstract] Context: There are no data on mortality of acromegaly diagnosed in older individuals. Objective: This work aimed to compare clinical characteristics, growth hormone-related comorbidities, therapeutic approaches, and mortality rate of patients diagnosed before or after 2010 and to assess overall mortality rate compared with the general Spanish population. Methods: A retrospective evaluation was conducted among Spanish tertiary care centers of 118 patients diagnosed with acromegaly at age 65 or older. Kaplan-Meier curves were constructed to trace survival, and Cox proportional hazard models were used to assess the risk factors associated with mortality. We also compared mortality with that of the Spanish population by using age- and sex-adjusted standardized mortality ratios (SMRs). Results: No differences were found in first-line treatment or biochemical control, between both periods except for faster biochemical control after 2010. Twenty-nine (24.6%) patients died, without differences between groups, and had a median of follow-up 8.6 years (103, [72.3] months). Overall SMR was 1.02 (95% CI, 0.57-1.54), (0.60; 95% CI, 0.35-1.06) for men and (1.80; 95% CI, 1.07-2.94) for women. The most common cause of death was cardiovascular disease (CVD). Conclusion: The mortality in patients with acromegaly diagnosed in older individuals was no different between both periods, and there was no overall SMR difference compared with the general Spanish population. However, the SMR was higher in women. As CVD is the leading cause of mortality, it seems advisable to initiate an intense CVD protective treatment as soon as acromegaly is diagnosed, particularly in women, in addition to tight acromegaly control to prevent excess mortality.